Denali Advisors LLC Has $7.59 Million Position in Amphastar Pharmaceuticals, Inc. $AMPH

Denali Advisors LLC boosted its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 41.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 375,965 shares of the company’s stock after buying an additional 109,500 shares during the quarter. Denali Advisors LLC owned approximately 0.88% of Amphastar Pharmaceuticals worth $7,587,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. Marshall Wace LLP raised its position in shares of Amphastar Pharmaceuticals by 41.6% during the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock worth $33,134,000 after acquiring an additional 363,216 shares during the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Amphastar Pharmaceuticals by 382.9% in the third quarter. Arrowstreet Capital Limited Partnership now owns 392,310 shares of the company’s stock valued at $10,455,000 after acquiring an additional 311,071 shares during the last quarter. UBS Group AG boosted its holdings in Amphastar Pharmaceuticals by 367.2% in the third quarter. UBS Group AG now owns 312,274 shares of the company’s stock valued at $8,322,000 after acquiring an additional 245,440 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in Amphastar Pharmaceuticals in the second quarter worth about $4,689,000. Finally, Dimensional Fund Advisors LP increased its position in Amphastar Pharmaceuticals by 12.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after purchasing an additional 228,262 shares during the period. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $21.74 on Thursday. The firm has a market capitalization of $924.82 million, a P/E ratio of 12.86, a PEG ratio of 4.51 and a beta of 0.89. Amphastar Pharmaceuticals, Inc. has a 1 year low of $16.65 and a 1 year high of $31.26. The business has a 50-day moving average of $19.91 and a 200-day moving average of $21.05. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The business had revenue of $183.90 million for the quarter, compared to the consensus estimate of $179.92 million. On average, equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AMPH. Zacks Research upgraded shares of Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Bank of America reiterated an “underperform” rating and set a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, June 29th. Weiss Ratings reissued a “sell (d+)” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, July 8th. Barclays increased their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company an “equal weight” rating in a report on Tuesday. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Six research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Amphastar Pharmaceuticals currently has a consensus rating of “Reduce” and a consensus price target of $22.50.

Insider Activity at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 8,180 shares of Amphastar Pharmaceuticals stock in a transaction on Friday, August 7th. The shares were sold at an average price of $22.48, for a total transaction of $183,886.40. Following the transaction, the chief financial officer directly owned 172,846 shares of the company’s stock, valued at $3,885,578.08. This trade represents a 4.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard K. Prins sold 7,973 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $20.30, for a total transaction of $161,851.90. Following the completion of the transaction, the director directly owned 29,625 shares of the company’s stock, valued at $601,387.50. This trade represents a 21.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 29.60% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.